Twist Bioscience has launched the customisable Twist MRD Rapid 500 Panel to advance research and development in detecting minimal residual disease (MRD) in cancer screening.
The new solution can be used to design, manufacture and ship selected targets of interest.
It can be added to a standard next-generation sequencing (NGS) workflow to provide complete customisable and low-cost panels that can detect MRD in five days.
The new Twist MRD Rapid 500 Panel targets up to five hundred variants with each test and spans 12 tests on each panel.
It is custom-designed to maximise the coverage uniformity across all target regions and limits the need for over-sequencing.
Using hybrid capture technology, the solution can sequence specific regions that may offer customised disease insights to researchers.
This can help to improve sequencing sensitivity and expand utility.
The company stated that the technology offers broad coverage compared to polymerase chain reaction (PCR) or amplicon sequencing methods.
Twist Bioscience CEO and co-founder Emily Leproust said: “When it comes to monitoring MRD, which can inform treatment options for patients with cancer, there is no time to waste.
“With the Twist MRD Rapid 500 Panel, we are able to rapidly create custom panels for our research customers, including panels specific to each sample’s unique genetic variance of cancer in as few as five days.
“Through this panel, we facilitate the research and development of our customers in developing new MRD solutions that clinicians can use to benefit their patients.”
MRD testing helps to track and predict the progression of cancer over time as well as determine the presence of tumour cells during treatment.